Advanced
  Home Compare Reports

Comparison with Similar Reports

Benign Prostatic Hyperplasia Treatment Market by Type [Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutaste...

by Type [Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA], End User (Hospitals) - Global Forecast to 2026

Publisher:        MarketsandMarkets

# of Pages:        154

Rating: 

1 User License $4,950

Publication Date:  February, 2021

Price:       $4,950 / User License




TABLE OF CONTENTS

 

1              INTRODUCTION                23

1.1          OBJECTIVES OF THE STUDY          23

1.2          MARKET DEFINITION      23

1.2.1      INCLUSIONS AND EXCLUSIONS  24

1.3          MARKET SCOPE                24

1.3.1      MARKETS COVERED        24

1.3.2      YEARS CONSIDERED FOR THE STUDY        25

1.4          CURRENCY          25

1.5          STAKEHOLDERS 25

1.6          LIMITATIONS OF THE CURRENT EDITION               25

2              RESEARCH METHODOLOGY         27

2.1          RESEARCH DATA               27

FIGURE 1             RESEARCH DESIGN          27

2.1.1      SECONDARY DATA           28

2.1.1.1   Key data from secondary sources             28

2.1.2      PRIMARY DATA 29

FIGURE 2             BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION          29

2.1.2.1   Key data from primary sources  29

2.2          MARKET SIZE ESTIMATION          30

FIGURE 3             RESEARCH METHODOLOGY: HYPOTHESIS BUILDING         30

2.2.1      BOTTOM-UP APPROACH              31

FIGURE 4             BPH TREATMENT MARKET: BOTTOM-UP APPROACH       31

2.2.2      GROWTH FORECAST       32

2.2.3      TOP-DOWN APPROACH                32

FIGURE 5             BPH TREATMENT MARKET: TOP-DOWN APPROACH         32

2.3          MARKET BREAKDOWN AND DATA TRIANGULATION        33

FIGURE 6             DATA TRIANGULATION METHODOLOGY               33

2.4          ASSUMPTIONS FOR THE STUDY 34

3              EXECUTIVE SUMMARY  35

FIGURE 7             BPH TREATMENT MARKET, BY TYPE, 2021 VS. 2026 (USD BILLION)              35

FIGURE 8             BPH TREATMENT MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)   36

FIGURE 9             BPH TREATMENT MARKET, BY REGION, 2021 VS. 2026 (USD BILLION)       36

4              PREMIUM INSIGHTS       37

4.1          BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET OVERVIEW        37

FIGURE 10           INCREASING PREVALENCE OF BPH IS THE MAJOR FACTOR DRIVING THE GROWTH OF THIS MARKET          37

4.2          NORTH AMERICA: BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY TYPE (2020)            37

FIGURE 11           DRUG TREATMENT TO DOMINATE THE NORTH AMERICAN MARKET IN 2020         37

4.3          GEOGRAPHICAL SNAPSHOT OF THE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET       38

FIGURE 12           JAPAN TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD              38

5              MARKET OVERVIEW       39

5.1          INTRODUCTION                39

5.2          MARKET DYNAMICS       39

FIGURE 13           BPH TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES  39

5.2.1      DRIVERS               40

5.2.1.1   Increasing prevalence of benign prostatic hyperplasia    40

FIGURE 14           SHARE OF MALE POPULATION AGED 65 AND ABOVE, GLOBAL (2015-2019)            40

5.2.1.2   Increasing obesity           40

5.2.1.3   Rising preference for minimally invasive surgeries            41

5.2.1.4   Investments, funds, and grants for research in BPH treatment   41

5.2.1.5   Availability of reimbursement for surgeries         42

TABLE 1                CPT CODES FOR BPH SURGERIES               42

5.2.2      RESTRAINTS       42

5.2.2.1   Side-effects associated with BPH medications    42

TABLE 2                SIDE-EFFECTS OF BPH DRUGS     43

5.2.3      OPPORTUNITIES               43

5.2.3.1   Emerging markets           43

5.2.3.2   Promising product pipeline          44

TABLE 3                PIPELINE DRUGS              44

5.2.4      CHALLENGES      44

5.2.4.1   Low awareness regarding prostate health among men   44

5.2.4.2   Product recalls in the BPH treatment market       44

TABLE 4                PRODUCT RECALLS IN THE BPH TREATMENT MARKET      45

5.3          VALUE CHAIN ANALYSIS               45

FIGURE 15           VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE                45

5.4          SUPPLY CHAIN ANALYSIS              46

FIGURE 16           DIRECT DISTRIBUTION—THE PREFERRED STRATEGY OF PROMINENT COMPANIES              47

5.5          ECOSYSTEM ANALYSIS   47

FIGURE 17           ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY       47

FIGURE 18           ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES MARKET          48

5.6          REGULATORY SCENARIO               48

5.6.1      PHARMACEUTICAL INDUSTRY    48

5.6.1.1   Regulatory requirements             48

5.6.1.1.1               EU regulations   48

5.6.1.1.2               US regulations   49

5.6.2      MEDICAL DEVICES INDUSTRY      49

TABLE 5                LIST OF REGULATORY AUTHORITIES         49

5.6.2.1   Regulatory requirements             50

5.6.2.1.1               EU regulations   50

5.6.2.1.2               US regulations   51

5.7          AVERAGE SELLING PRICE TREND               51

TABLE 6                AVERAGE SELLING PRICE OF BPH DRUGS              51

TABLE 7                AVERAGE SELLING PRICE OF BPH TREATMENT PROCEDURES        52

TABLE 8                AVERAGE SELLING PRICE OF DEVICES USED IN BPH TREATMENT PROCEDURES    52

5.8          TECHNOLOGY ANALYSIS               52

5.9          PESTLE ANALYSIS             54

5.10        COVID-19 IMPACT ANALYSIS ON THE BPH TREATMENT MARKET                55

5.11        EPIDEMIOLOGY OF BENIGN PROSTATIC HYPERPLASIA (2019)       55

TABLE 9                BPH: COUNTRY-WISE PREVALENCE, 2019              55

6              BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY TYPE             56

6.1          INTRODUCTION                57

TABLE 10              BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY TYPE,  2018–2026 (USD MILLION)     57

6.2          DRUG TREATMENT          57

TABLE 11              BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)  57

TABLE 12              BPH DRUG TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION)              58

6.2.1      ALPHA BLOCKERS             58

TABLE 13              BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,  2018–2026 (USD MILLION)      58

TABLE 14              BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY REGION,  2018–2026 (USD MILLION)               59

6.2.1.1   Tamsulosin         59

6.2.1.1.1               Tamsulosin has been prescribed for BPH since 2000         59

TABLE 15              TAMSULOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)  59

6.2.1.2   Silodosin              60

6.2.1.2.1               Benefits of silodosin and launch of generics support market growth        60

TABLE 16              SILODOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)       60

6.2.1.3   Alfuzosin             60

6.2.1.3.1               Side-effects and fewer generic launches have hindered market growth to some extent                60

TABLE 17              ALFUZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)      61

6.2.1.4   Doxazosin           61

6.2.1.4.1               Doxazosin was introduced in 2005 and has seen many generic launches since      61

TABLE 18              DOXAZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)     61

6.2.1.5   Other alpha blockers      62

TABLE 19              OTHER ALPHA BLOCKERS MARKET, BY REGION, 2018–2026 (USD MILLION)            62

6.2.2      5-ALPHA REDUCTASE INHIBITORS             62

TABLE 20              BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)             62

TABLE 21              BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY REGION, 2018–2026 (USD MILLION)      63

6.2.2.1   Dutasteride        63

6.2.2.1.1               Availability of generics post-patent expiry support market growth            63

TABLE 22              DUTASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION)  63

6.2.2.2   Finasteride         64

6.2.2.2.1               Finasteride provides a range of benefits but is less effective than alpha blockers in improving LUTS          64

TABLE 23              FINASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION)   64

6.2.3      OTHER DRUG CLASSES   64

TABLE 24              OTHER BPH DRUG CLASSES MARKET, BY REGION, 2018–2026 (USD MILLION)       65

6.3          SURGICAL TREATMENT 65

TABLE 25              BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)            65

TABLE 26              BPH SURGICAL TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION)      66

6.3.1      TRANSURETHRAL RESECTION OF THE PROSTATE                66

6.3.1.1   TURP is the gold standard for BPH treatment      66

TABLE 27              BPH SURGICAL TREATMENT MARKET FOR TURP, BY REGION, 2018–2026 (USD MILLION)                67

6.3.2      LASER SURGERY                67

6.3.2.1   Evolution in lasers and high efficacy have supported the demand for laser surgery           67

TABLE 28              BPH SURGICAL TREATMENT MARKET FOR LASER SURGERY, BY REGION,  2018–2026 (USD MILLION)          67

6.3.3      TRANSURETHRAL MICROWAVE THERMOTHERAPY            68

6.3.3.1   TUMT has a lower risk of bleeding and requires no hospital stay, which has driven preference    68

TABLE 29              BPH SURGICAL TREATMENT MARKET FOR TUMT, BY REGION, 2018–2026 (USD MILLION)               68

6.3.4      UROLIFT THERAPY           68

6.3.4.1   Low rate of post-implantation surgical intervention indicates high effectiveness of UroLift and the potential for adoption              68

TABLE 30              BPH SURGICAL TREATMENT MARKET FOR UROLIFT THERAPY, BY REGION,  2018–2026 (USD MILLION)      69

6.3.5      TRANSURETHRAL NEEDLE ABLATION OF THE PROSTATE 69

6.3.5.1   Reimbursement coverage and growing preference for TUNA drive market growth           69

TABLE 31              BPH SURGICAL TREATMENT MARKET FOR TUNA, BY REGION, 2018–2026 (USD MILLION)               70

6.3.6      REZŪM THERAPY              70

6.3.6.1   The cost-effectiveness and efficacy of Rezūm water vapor therapy are driving demand for the procedure            70

TABLE 32              BPH SURGICAL TREATMENT MARKET FOR REZŪM THERAPY, BY REGION,  2018–2026 (USD MILLION)        71

6.3.7      PROSTATIC STENTING    71

6.3.7.1   Prostatic stenting is a temporary measure conducted under local anesthesia       71

TABLE 33              BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTING, BY REGION,  2018–2026 (USD MILLION)                71

6.3.8      OTHER SURGERIES           72

TABLE 34              OTHER BPH SURGICAL TREATMENTS MARKET, BY REGION, 2018–2026 (USD MILLION)     72

7              BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET,  BY END USER  73

7.1          INTRODUCTION                74

TABLE 35              BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY END USER,  2018–2026 (USD MILLION)          74

7.2          HOME HEALTHCARE        74

7.2.1      LARGE PATIENT POPULATION USING MEDICATIONS TO DRIVE THE GROWTH OF THE SEGMENT  74

TABLE 36              BPH TREATMENT MARKET FOR HOME HEALTHCARE, BY REGION,  2018–2026 (USD MILLION)        75

7.3          HOSPITALS & CLINICS     75

7.3.1      RISING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES TO DRIVE THE GROWTH OF THE SEGMENT   75

TABLE 37              BPH TREATMENT MARKET FOR HOSPITALS & CLINICS, BY REGION,  2018–2026 (USD MILLION)     76

8              BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET,  BY REGION      77

8.1          INTRODUCTION                78

TABLE 38              BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, BY REGION,  2018–2026 (USD MILLION)              78

8.2          NORTH AMERICA             79

FIGURE 19           NORTH AMERICA: BPH TREATMENT MARKET SNAPSHOT               79

TABLE 39              NORTH AMERICA: BPH TREATMENT MARKET, BY COUNTRY, 2018–2026 (USD MILLION)  79

TABLE 40              NORTH AMERICA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)             80

TABLE 41              NORTH AMERICA: BPH DRUG TREATMENT MARKET, BY CLASS,  2018–2026 (USD MILLION)            80

TABLE 42              NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)             80

TABLE 43              NORTH AMERICA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE,  2018–2026 (USD MILLION)    81

TABLE 44              NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE,  2018–2026 (USD MILLION)      81

TABLE 45              NORTH AMERICA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)  81

8.2.1      US          82

8.2.1.1   The US holds the largest share of the North American market    82

TABLE 46              US: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)          82

TABLE 47              US: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)          82

TABLE 48              US: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,  2018–2026 (USD MILLION)              83

TABLE 49              US: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)  83

TABLE 50              US: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)    83

TABLE 51              US: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)               84

8.2.2      CANADA              84

8.2.2.1   Rising geriatric population and product approvals to support market growth        84

TABLE 52              CANADA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)              84

TABLE 53              CANADA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)              85

TABLE 54              CANADA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,  2018–2026 (USD MILLION)  85

TABLE 55              CANADA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)      85

TABLE 56              CANADA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)        86

TABLE 57              CANADA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)   86

8.3          EUROPE               86

TABLE 58              EUROPE: BPH TREATMENT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)     86

TABLE 59              EUROPE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)               87

TABLE 60              EUROPE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)               87

TABLE 61              EUROPE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,  2018–2026 (USD MILLION)   87

TABLE 62              EUROPE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)       87

TABLE 63              EUROPE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)         88

TABLE 64              EUROPE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)    88

8.3.1      GERMANY           88

8.3.1.1   Increasing healthcare expenditure to support German market growth   88

TABLE 65              GERMANY: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)          89

TABLE 66              GERMANY: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)          89

TABLE 67              GERMANY: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,  BY TYPE, 2018, 2018–2026 (USD MILLION)             89

TABLE 68              GERMANY: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)   89

TABLE 69              GERMANY: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)     90

TABLE 70              GERMANY: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)                90

8.3.2      UK          90

8.3.2.1   Availability of innovative treatment options to drive the market in the UK            90

TABLE 71              UK: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)          91

TABLE 72              UK: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)          91

TABLE 73              UK: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,  2018–2026 (USD MILLION)              91

TABLE 74              UK: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)  91

TABLE 75              UK: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)    92

TABLE 76              UK: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)               92

8.3.3      FRANCE                92

8.3.3.1   Rising geriatric population to accelerate the growth of the market            92

TABLE 77              FRANCE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)               93

TABLE 78              FRANCE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)               93

TABLE 79              FRANCE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,  2018–2026 (USD MILLION)   93

TABLE 80              FRANCE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)        93

TABLE 81              FRANCE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)          94

TABLE 82              FRANCE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)     94

8.3.4      REST OF EUROPE              94

TABLE 83              ROE: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)       95

TABLE 84              ROE: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)       95

TABLE 85              ROE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018,  2018–2026 (USD MILLION)                95

TABLE 86              ROE: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)                95

TABLE 87              ROE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)  96

TABLE 88              ROE: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)             96

8.4          ASIA PACIFIC     97

FIGURE 20           ASIA PACIFIC: BPH TREATMENT MARKET SNAPSHOT       97

TABLE 89              ASIA PACIFIC: BPH TREATMENT MARKET, BY COUNTRY, 2018–2026 (USD MILLION)           98

TABLE 90              ASIA PACIFIC: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)     98

TABLE 91              ASIA PACIFIC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)     98

TABLE 92              ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018, 2018–2026 (USD MILLION)             99

TABLE 93              ASIA PACIFIC: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE,  2018–2026 (USD MILLION)            99

TABLE 94              ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)               99

TABLE 95              ASIA PACIFIC: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)          100

8.4.1      JAPAN  100

8.4.1.1   Japan holds the largest share of the APAC market            100

TABLE 96              JAPAN: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)  100

TABLE 97              JAPAN: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)  101

TABLE 98              JAPAN: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018,  2018–2026 (USD MILLION)                101

TABLE 99              JAPAN: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)          101

TABLE 100            JAPAN: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)            102

TABLE 101            JAPAN: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)       102

8.4.2      CHINA   102

8.4.2.1   Increasing obese population to support market growth 102

TABLE 102            CHINA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)  103

TABLE 103            CHINA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)  103

TABLE 104            CHINA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018,  2018–2026 (USD MILLION)                103

TABLE 105            CHINA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)           104

TABLE 106            CHINA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)             104

TABLE 107            CHINA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)        104

8.4.3      INDIA    105

8.4.3.1   Rising prevalence of obesity to accelerate market growth in India             105

TABLE 108            INDIA: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)    105

TABLE 109            INDIA: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)    105

TABLE 110            INDIA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018,  2018–2026 (USD MILLION)                105

TABLE 111            INDIA: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)            106

TABLE 112            INDIA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)              106

TABLE 113            INDIA: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)         106

8.4.4      REST OF ASIA PACIFIC    107

TABLE 114            ROAPAC: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)              107

TABLE 115            ROAPAC: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)              107

TABLE 116            ROAPAC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,  2018–2026 (USD MILLION)  108

TABLE 117            ROAPAC: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)       108

TABLE 118            ROAPAC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)         108

TABLE 119            ROAPAC: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)    109

8.5          REST OF THE WORLD       109

TABLE 120            ROW: BPH TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)     109

TABLE 121            ROW: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)     110

TABLE 122            ROW: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018,  2018–2026 (USD MILLION)                110

TABLE 123            ROW: BPH TREATMENT MARKET FOR 5-ARIS, BY TYPE, 2018–2026 (USD MILLION)              110

TABLE 124            ROW: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2018–2026 (USD MILLION)                111

TABLE 125            ROW: BPH TREATMENT MARKET, BY END USER, 2018–2026 (USD MILLION)           111

9              COMPETITIVE LANDSCAPE & COMPANY PROFILES            112

9.1          COMPETITIVE LANDSCAPE           112

9.1.1      OVERVIEW          112

FIGURE 21           KEY DEVELOPMENTS IN THE BPH TREATMENT MARKET, JANUARY 2017–JANUARY 2021  112

FIGURE 22           MARKET EVOLUTION FRAMEWORK: JANUARY 2017 TO JANUARY 2021   113

9.1.2      MARKET SHARE ANALYSIS, 2019                114

9.1.2.1   BPH Drug Treatment Market Share Analysis, 2019             114

FIGURE 23           BPH DRUG TREATMENT MARKET SHARE ANALYSIS, 2019               114

9.1.2.2   BPH Surgical Treatment Market Share Analysis, 2019       115

FIGURE 24           BPH SURGICAL TREATMENT MARKET SHARE ANALYSIS, 2019       115

9.1.3      COMPETITIVE SCENARIO              115

9.1.3.1   Product launches and approvals                115

TABLE 126            KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2017−JANUARY 2021              116

9.1.3.2   Acquisitions        116

TABLE 127            KEY ACQUISITIONS, JANUARY 2017−JANUARY 2021         116

9.1.3.3   Agreements and collaborations 117

TABLE 128            KEY AGREEMENTS AND COLLABORATIONS, JANUARY 2017−JANUARY 2021          117

9.1.3.4   Expansions         117

TABLE 129            KEY EXPANSIONS, JANUARY 2017−JANUARY 2021             117

9.1.3.5   Other developments     117

TABLE 130            OTHER DEVELOPMENTS, JANUARY 2017−JANUARY 2021                117

9.1.4      COMPANY EVALUATION MATRIX             118

9.1.4.1   Stars      118

9.1.4.2   Emerging Leaders            118

9.1.4.3   Pervasive Companies     118

9.1.4.4   Participants        118

FIGURE 25           BPH TREATMENT MARKET: COMPANY EVALUATION MATRIX, 2019          119

9.1.5      COMPETITIVE LEADERSHIP MAPPING (START-UPS AND SMES)   120

9.1.5.1   Progressive Companies 120

9.1.5.2   Starting Blocks   120

9.1.5.3   Responsive Companies 120

9.1.5.4   Dynamic Companies       120

FIGURE 26           BPH TREATMENT MARKET: VENDOR DIVE MATRIX FOR SMES AND START-UPS, 2019        121

9.2          COMPANY PROFILES      122

(Business overview, Products offered, Recent Developments, MNM view)*

9.2.1      GLAXOSMITHKLINE         122

FIGURE 27           GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)   122

9.2.2      ASTELLAS PHARMA         124

FIGURE 28           ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2019)  124

9.2.3      MERCK 126

FIGURE 29           MERCK: COMPANY SNAPSHOT (2019)    126

9.2.4      ELI LILLY AND COMPANY               128

FIGURE 30           ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019)  128

9.2.5      TELEFLEX INCORPORATED            130

FIGURE 31           TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2019)               130

9.2.6      ABBOTT LABORATORIES                132

FIGURE 32           ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019)   132

9.2.7      BOSTON SCIENTIFIC CORPORATION        133

FIGURE 33           BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2019)           133

9.2.8      PFIZER  135

FIGURE 34           PFIZER: COMPANY SNAPSHOT (2019)     135

9.2.9      OLYMPUS CORPORATION            136

FIGURE 35           OLYMPUS CORPORATION: COMPANY SNAPSHOT (2019)               136

9.2.10    ALEMBIC              138

FIGURE 36           ALEMBIC: COMPANY SNAPSHOT (2019) 138

9.2.11    ASAHI KASEI CORPORATION       139

FIGURE 37           ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2019)          139

9.2.12    ALLERGAN          141

FIGURE 38           ALLERGAN: COMPANY SNAPSHOT (2019)             141

9.2.13    COLOPLAST GROUP        142

FIGURE 39           COLOPLAST GROUP: COMPANY SNAPSHOT (2020)           142

9.2.14    IPG PHOTONICS CORPORATION                144

FIGURE 40           IPG PHOTONICS CORPORATION: COMPANY SNAPSHOT (2019)   144

9.2.15    KARL STORZ SE & CO. KG              145

9.2.16    RICHARD WOLF GMBH  145

9.2.17    LUMENIS LTD.   146

9.2.18    UNILAB, INC.     146

9.2.19    PHAREX HEALTH CORP   147

9.2.20    BIOLITEC AG       147

9.2.21    UROLOGIX, LLC.                148

9.2.22    ADVIN HEALTH CARE      148

9.2.23    MEDIFOCUS INC.             148

9.2.24    ASCLEPION LASER TECHNOLOGIES GMBH             148

9.2.25    PNN MEDICAL A/S           148

9.2.26    SURGICAL LASERS INC.  149

9.2.27    QUANTA SYSTEM             149

9.2.28    ALLIUM LTD        149

9.2.29    SRS MEDICAL     149

*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

10           APPENDIX           150

10.1        INDUSTRY INSIGHTS       150

10.2        DISCUSSION GUIDE        151

10.3        KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL   155

10.4        AVAILABLE CUSTOMIZATIONS   157

10.5        RELATED REPORTS           157

10.6        AUTHOR DETAILS             158

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Lateral Flow Assay Components Market by Type, Application Type (Clinical Testing (Infectious, Cardiac Marker Test) Veterinary, Food Safety), Technique...

Publisher:        MarketsandMarkets

# of Pages:        224

Rating: 

1 User License $4,950

Publication Date:  April, 2022

Price:       $4,950 / User License




1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 CATEGORY-WISE INCLUSIONS AND EXCLUSIONS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 LATERAL FLOW ASSAY COMPONENTS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED FOR THE STUDY 35
1.4 CURRENCY 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
1.5 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 38
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primaries 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 41
FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 45
2.4 KEY INDUSTRY INSIGHTS 46
2.5 LIMITATIONS 46
2.5.1 METHODOLOGY-RELATED LIMITATIONS 46
2.6 RISK ASSESSMENT 47
2.7 ASSUMPTIONS FOR THE STUDY 47
 
3 EXECUTIVE SUMMARY 48
FIGURE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 48
FIGURE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2022 VS. 2027 (USD MILLION) 49
FIGURE 10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 50
FIGURE 11 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 51
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 LATERAL FLOW ASSAY COMPONENTS MARKET OVERVIEW 53
FIGURE 13 RISING NUMBER OF LOCAL MANUFACTURERS FOR COMPONENTS IS DRIVING THE GROWTH OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 53
4.2 REGIONAL MIX: LATERAL FLOW ASSAY COMPONENTS MARKET 54
FIGURE 14 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
4.3 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE AND COUNTRY 55
FIGURE 15 MEMBRANES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 55
4.4 LATERAL FLOW ASSAY COMPONENTS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56
4.5 LATERAL FLOW ASSAY COMPONENTS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 57
5.2.1 DRIVERS 58
5.2.1.1 Growing demand for lateral flow assay kits due
to the COVID-19 pandemic 58
5.2.1.2 Growing usage of home-based lateral flow assay devices 58
5.2.1.3 Growing demand for point-of-care testing 58
5.2.1.4 Increasing public-private investments to develop lateral flow assays 59
5.2.2 RESTRAINTS 59
5.2.2.1 Availability of alternative diagnostic technologies 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Evolving applications of lateral flow assays 59
5.2.4 CHALLENGES 60
5.2.4.1 Requirement of specialized storage and shipping facilities for membranes 60
5.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES (YC-YCC) IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
FIGURE 16 YC–YCC SHIFT IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 61
5.5 AVERAGE SELLING PRICE TREND 61
TABLE 2 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY COMPONENTS,
BY REGION, 2021 (USD) 61
5.6 ECOSYSTEM MARKET MAP 62
FIGURE 17 ECOSYSTEM: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 62
5.7 PATENT ANALYSIS 63
5.7.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS 63
FIGURE 18 GLOBAL PATENT PUBLICATION TRENDS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2016–2021 64
5.7.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 64
FIGURE 19 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAYS COMPONENTS, 2016–2021 64
5.8 VALUE CHAIN ANALYSIS 65
5.9 REGULATORY LANDSCAPE 66
TABLE 3 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY PRODUCTS, BY COUNTRY/REGION 66
5.9.1 NORTH AMERICA 66
5.9.2 EUROPE 67
5.9.3 ASIA PACIFIC 67
5.9.3.1 India 67
5.9.3.2 China 67
5.9.3.3 Japan 68
5.10 TECHNOLOGY ANALYSIS 69
5.10.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS 69
5.11 KEY CONFERENCES & EVENTS DURING 2021–2023 69
TABLE 4 LATERAL FLOW ASSAY COMPONENTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 69
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 70
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 70
FIGURE 20 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
TABLE 5 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
5.12.2 BUYING CRITERIA 71
FIGURE 21 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
TABLE 6 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
5.13 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 7 LATERAL FLOW ASSAY COMPONENTS MARKET:
PORTER’S FIVE FORCES ANALYSIS 72
5.13.1 THREAT FROM NEW ENTRANTS 72
5.13.2 THREAT FROM SUBSTITUTES 72
5.13.3 BARGAINING POWER OF BUYERS 73
5.13.4 BARGAINING POWER OF SUPPLIERS 73
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 73
6 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE 74
6.1 INTRODUCTION 75
TABLE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 75
6.2 MEMBRANES 75
TABLE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE,
2020–2027 (USD MILLION) 76
TABLE 10 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 76
6.2.1 NITROCELLULOSE MEMBRANES 77
6.2.1.1 Advantages of nitrocellulose membranes such as high protein-binding affinity and compatibility with a wide range of detection methods to drive market growth 77
TABLE 11 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 12 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (1 X 1 M SHEETS), BY REGION, 2020–2027 (IN THOUSANDS) 78
TABLE 13 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (20 MM X 1 M ROLLS), BY REGION, 2020–2027 (IN MILLIONS) 78
6.2.2 OTHER MEMBRANES 78
TABLE 14 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 79
6.3 PADS 80
TABLE 15 EXAMPLES OF DIFFERENT MATERIALS USED IN MANUFACTURING LATERAL FLOW ASSAY PADS 80
TABLE 16 LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 80
TABLE 17 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PADS, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.3.1 SAMPLE PADS 81
6.3.1.1 Ability to promote even and controlled distribution of samples to drive market growth 81
TABLE 18 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SAMPLE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 82
6.3.2 CONJUGATE PADS 82
6.3.2.1 Conjugate pads play an important role in controlling the performance of lateral flow immunoassays 82
TABLE 19 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CONJUGATE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
6.3.3 ABSORBENT PADS 84
6.3.3.1 Absorbent pads prevent backflow—a key factor driving market growth 84
TABLE 20 LATERAL FLOW ASSAY COMPONENTS MARKET FOR ABSORBENT PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 OTHER COMPONENTS 84
TABLE 21 OTHER LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
7 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION 86
7.1 INTRODUCTION 87
TABLE 22 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 87
7.2 CLINICAL TESTING 87
TABLE 23 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 24 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 88
7.2.1 INFECTIOUS DISEASE TESTING 89
7.2.1.1 Rising demand for infectious disease testing in emerging markets to drive market growth 89
TABLE 25 LATERAL FLOW ASSAY COMPONENTS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 89
7.2.2 PREGNANCY & FERTILITY TESTING 90
7.2.2.1 Growing infertility levels due to changing lifestyles—a key factor driving market growth 90
TABLE 26 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.2.3 CARDIAC MARKER TESTING 91
7.2.3.1 Rising prevalence of cardiovascular diseases and growing government support to drive growth in this market segment 91
TABLE 27 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.2.4 CHOLESTEROL TESTING/LIPID PROFILING 92
7.2.4.1 Growing prevalence of obesity and CVD—
a key factor driving market growth 92
TABLE 28 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CHOLESTEROL TESTING/LIPID PROFILING, BY COUNTRY, 2020–2027 (USD MILLION) 93
7.2.5 DRUGS-OF-ABUSE TESTING 93
7.2.5.1 Technological advancements and a growing focus on workplace
drug testing are driving market growth 93
TABLE 29 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.2.6 OTHER CLINICAL TESTING APPLICATIONS 94
TABLE 30 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER CLINICAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3 VETERINARY DIAGNOSTICS 95
7.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) TO DRIVE MARKET GROWTH 95
TABLE 31 LATERAL FLOW ASSAY COMPONENTS MARKET FOR VETERINARY DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
7.4 FOOD SAFETY & ENVIRONMENTAL TESTING 96
7.4.1 HIGH SENSITIVITY AND EASE OF USE ARE KEY FACTORS DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING 96
TABLE 32 LATERAL FLOW ASSAY COMPONENTS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.5 DRUG DEVELOPMENT & QUALITY TESTING 97
7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE MARKET GROWTH IN THE COMING YEARS 97
TABLE 33 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE 99
8.1 INTRODUCTION 100
TABLE 34 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 100
8.2 SANDWICH ASSAYS 100
8.2.1 SANDWICH ASSAYS PROVIDE HIGHER LEVELS OF ASSAY SENSITIVITY AND SPECIFICITY THAN OTHER ASSAY TECHNIQUES—A KEY FACTOR DRIVING GROWTH IN THIS MARKET SEGMENT 100
TABLE 35 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SANDWICH ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
8.3 COMPETITIVE ASSAYS 101
8.3.1 REDUCED SELECTIVITY AND SENSITIVITY OF COMPETITIVE ASSAYS IN RELATION TO SANDWICH ASSAYS COULD HAMPER MARKET GROWTH 101
TABLE 36 LATERAL FLOW ASSAY COMPONENTS MARKET FOR COMPETITIVE ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 102
8.4 MULTIPLEX DETECTION ASSAYS 102
8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET GROWTH 102
TABLE 37 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 38 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 105
9.2 MEDICAL DEVICE MANUFACTURING COMPANIES 105
9.2.1 INCREASING USE OF POC TESTS IS DRIVING THE ADOPTION OF LATERAL FLOW ASSAY COMPONENTS AMONG MEDICAL DEVICE MANUFACTURING COMPANIES 105
TABLE 39 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE MANUFACTURING COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
9.3 MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES 106
9.3.1 GROWING INCLINATION TOWARD FAST AND EARLY DIAGNOSIS, ESPECIALLY IN RELATION TO THE CURRENT COVID-19 SCENARIO, WILL DRIVE MARKET GROWTH 106
TABLE 40 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES, BY COUNTRY,
2020–2027 (USD MILLION) 107
 
10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION 108
10.1 INTRODUCTION 109
FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH IN THE LATERAL FLOW ASSAY COMPONENTS MARKET DURING THE FORECAST PERIOD 109
TABLE 41 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
10.2 NORTH AMERICA 110
TABLE 42 NORTH AMERICA: MACROECONOMIC INDICATORS 110
FIGURE 23 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 111
TABLE 43 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 44 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 45 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 112
TABLE 46 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 113
TABLE 47 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 48 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 49 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 114
TABLE 50 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 115
10.2.1 US 115
10.2.1.1 Increasing R&D investments and venture capital funding from both large and small firms towards the development of lateral flow assay diagnostics to drive market growth in the US 115
TABLE 51 US: MACROECONOMIC INDICATORS 116
TABLE 52 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 53 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 116
TABLE 54 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 117
TABLE 55 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 117
TABLE 56 US: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 57 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 118
TABLE 58 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 119
10.2.2 CANADA 119
10.2.2.1 Lateral flow assay components market in Canada is estimated to grow at a relatively lower rate than the US 119
TABLE 59 CANADA: MACROECONOMIC INDICATORS 119
TABLE 60 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 120
TABLE 61 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 120
TABLE 62 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 120
TABLE 63 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 64 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 65 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 122
TABLE 66 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.3 EUROPE 122
TABLE 67 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 68 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 69 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 123
TABLE 70 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 124
TABLE 71 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 72 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 73 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 125
TABLE 74 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Growing demand for POC testing to drive the lateral flow assay components market in Germany 126
TABLE 75 GERMANY: MACROECONOMIC INDICATORS 126
TABLE 76 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 77 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 127
TABLE 78 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 127
TABLE 79 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 80 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 81 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
TABLE 82 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
10.3.2 FRANCE 129
10.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth in France 129
TABLE 83 FRANCE: MACROECONOMIC INDICATORS 130
TABLE 84 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 85 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 130
TABLE 86 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 131
TABLE 87 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 88 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 89 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
TABLE 90 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3.3 UK 133
10.3.3.1 Severe impact of the second wave of COVID-19 in the first half of 2021 resulted in higher adoption of rapid COVID tests in the UK 133
TABLE 91 UK: MACROECONOMIC INDICATORS 134
TABLE 92 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 93 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 134
TABLE 94 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 135
TABLE 95 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 96 UK: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 97 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 136
TABLE 98 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 137
10.3.4 ITALY 137
10.3.4.1 Growing initiatives towards decentralization of medical services in Italy are contributing to the market growth in the country 137
TABLE 99 ITALY: MACROECONOMIC INDICATORS 137
TABLE 100 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 101 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 138
TABLE 102 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 138
TABLE 103 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 104 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 105 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 140
TABLE 106 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 140
10.3.5 SPAIN 140
10.3.5.1 Increasing focus of international organizations and domestic players on the development of POC products in the country to drive market growth 140
TABLE 107 SPAIN: MACROECONOMIC INDICATORS 141
TABLE 108 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 141
TABLE 109 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 142
TABLE 110 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 142
TABLE 111 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 112 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 113 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
TABLE 114 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 144
10.3.6 REST OF EUROPE 144
TABLE 115 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 116 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 145
TABLE 117 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 145
TABLE 118 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 119 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 120 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 146
TABLE 121 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 147
10.4 ASIA PACIFIC 147
FIGURE 24 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 148
TABLE 122 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 149
TABLE 123 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 149
TABLE 124 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 149
TABLE 125 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 150
TABLE 126 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 127 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 128 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 151
TABLE 129 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 152
10.4.1 CHINA 152
10.4.1.1 Higher exports of lateral flow assay components during the COVID-19 pandemic to drive market growth in the country 152
TABLE 130 CHINA: MACROECONOMIC INDICATORS 153
TABLE 131 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 132 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 153
TABLE 133 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 154
TABLE 134 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 135 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 136 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 155
TABLE 137 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 156
10.4.2 JAPAN 156
10.4.2.1 Increasing prevalence of age-related illnesses driving the growth of the lateral flow assay components market in Japan 156
TABLE 138 JAPAN: MACROECONOMIC INDICATORS 157
TABLE 139 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 157
TABLE 140 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 157
TABLE 141 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 158
TABLE 142 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 143 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 144 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 159
TABLE 145 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 160
10.4.3 INDIA 160
10.4.3.1 Increasing number of local manufacturers, growing healthcare concerns, and rising income levels to propel the growth of this market 160
TABLE 146 INDIA: MACROECONOMIC INDICATORS 160
TABLE 147 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 161
TABLE 148 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 161
TABLE 149 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 161
TABLE 150 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 151 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 152 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 163
TABLE 153 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 163
10.4.4 AUSTRALIA 164
10.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive the growth of the lateral flow assay components market in Australia 164
TABLE 154 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 155 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 164
TABLE 156 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 165
TABLE 157 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 158 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 159 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 166
TABLE 160 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.4.5 REST OF ASIA PACIFIC 167
TABLE 161 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 167
TABLE 162 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 168
TABLE 163 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 168
TABLE 164 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 165 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 166 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 169
TABLE 167 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
 
10.5 LATIN AMERICA 170
10.5.1 HIGH DEMAND FOR HIV POC DEVICES IN THE REGION TO SUPPORT THE GROWTH OF THE MARKET 170
TABLE 168 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 169 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 171
TABLE 170 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD
TYPE, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 172 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 173 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 173
TABLE 174 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANDING HEALTHCARE SERVICES DRIVES THE ADOPTION OF LATERAL FLOW ASSAYS 173
TABLE 175 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 174
TABLE 176 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 177 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 175
TABLE 178 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 175
TABLE 179 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 175
TABLE 180 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 181 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 176
TABLE 182 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 178
FIGURE 25 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
11.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
FIGURE 26 REVENUE SHARE ANALYSIS FOR THE KEY PLAYERS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 180
11.4 MARKET SHARE ANALYSIS 180
FIGURE 27 LATERAL FLOW ASSAY COMPONENTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 181
TABLE 183 LATERAL FLOW ASSAY COMPONENTS MARKET: DEGREE OF COMPETITION 182
11.5 R&D ASSESSMENT OF KEY PLAYERS 183
FIGURE 28 R&D EXPENDITURE: MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2018 VS. 2020 183
11.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 183
FIGURE 29 GEOGRAPHIC REVENUE ASSESSMENT: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 184
11.7 COMPANY EVALUATION QUADRANT 184
11.7.1 STARS 184
11.7.2 PERVASIVE PLAYERS 184
11.7.3 EMERGING LEADERS 185
11.7.4 PARTICIPANTS 185
FIGURE 30 LATERAL FLOW ASSAY COMPONENTS MARKET: COMPANY EVALUATION MATRIX, 2021 185
11.8 COMPETITIVE BENCHMARKING 186
11.8.1 OVERALL COMPANY FOOTPRINT 186
TABLE 184 OVERALL COMPANY FOOTPRINT (17 COMPANIES) 186
TABLE 185 COMPANY FOOTPRINT: BY TYPE (17 COMPANIES) 187
TABLE 186 COMPANY FOOTPRINT: BY REGION (17 COMPANIES) 188
11.9 COMPETITIVE SCENARIO 188
11.9.1 DEALS 189
TABLE 187 DEALS, JANUARY 2019–FEBRUARY 2022 189
11.9.2 OTHER DEVELOPMENTS 189
TABLE 188 OTHER DEVELOPMENTS, JANUARY 2019–FEBRUARY 2022 189
12 COMPANY PROFILES 190
12.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION (PALL CORPORATION AND CYTIVA LIFE SCIENCE) 190
TABLE 189 DANAHER CORPORATION: BUSINESS OVERVIEW 190
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 191
12.1.2 SARTORIUS STEDIM BIOTECH 195
TABLE 190 SARTORIUS STEDIM BIOTECH: BUSINESS OVERVIEW 195
12.1.3 MERCK KGAA 199
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 199
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2020) 200
12.1.4 AHLSTROM-MUNKSJÖ 204
TABLE 192 AHLSTROM-MUNKSJÖ: BUSINESS OVERVIEW 204
FIGURE 34 AHLSTROM-MUNKSJÖ: COMPANY SNAPSHOT (2020) 205
12.1.5 ADVANCED MICRODEVICES PVT. LTD. 208
TABLE 193 ADVANCED MICRODEVICES PVT. LTD.: BUSINESS OVERVIEW 208
12.1.6 DCN DIAGNOSTICS 210
TABLE 194 DCN DIAGNOSTICS: BUSINESS OVERVIEW 210
12.2 OTHER PLAYERS 211
12.2.1 FORTIS LIFE SCIENCES 211
TABLE 195 FORTIS LIFE SCIENCES: BUSINESS OVERVIEW 211
12.2.2 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD 212
TABLE 196 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD.:
BUSINESS OVERVIEW 212
12.2.3 AXIVA SICHEM BIOTECH 214
TABLE 197 AXIVA SICHEM BIOTECH: BUSINESS OVERVIEW 214
12.2.4 NUPORE FILTRATION SYSTEM 216
TABLE 198 NUPORE FILTRATION SYSTEM: BUSINESS OVERVIEW 216
12.2.5 BALLYA BIO 217
TABLE 199 BALLYA BIO: BUSINESS OVERVIEW 217
12.2.6 RUNBIO BIOTECH CO. LTD. 219
TABLE 200 RUNBIO BIOTECH CO. LTD.: BUSINESS OVERVIEW 219
12.2.7 NEENAH GESSNER 220
TABLE 201 NEENAH GESSNER: BUSINESS OVERVIEW 220
12.2.8 MAXIM BIOMEDICAL 221
TABLE 202 MAXIM BIOMEDICAL: BUSINESS OVERVIEW 221
12.2.9 CYTODIAGNOSTICS 222
TABLE 203 CYTODIAGNOSTICS: BUSINESS OVERVIEW 222
12.2.10 SENOVA GMBH 223
TABLE 204 SENOVA GMBH: BUSINESS OVERVIEW 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 224
13.1 DISCUSSION GUIDE 224
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
13.3 AVAILABLE CUSTOMIZATIONS 231
13.4 RELATED REPORTS 231
13.5 AUTHOR DETAILS 232

US Healthcare Environmental Services Market by Type (Janitorial/Core-Cleaning, Infection Control & Prevention, Front-of-house cleaning & Brand Experie...

Publisher:        MarketsandMarkets

# of Pages:        126

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION & SCOPE 15
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 16
1.2.2 MARKET SEGMENTATION 16
FIGURE 1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET SEGMENTATION 16
1.2.3 YEARS CONSIDERED FOR THE STUDY 17
1.3 CURRENCY 17
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 17
1.4 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH APPROACH 19
FIGURE 2 RESEARCH DESIGN 19
2.1.1 SECONDARY RESEARCH 20
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY RESEARCH 21
FIGURE 3 PRIMARY SOURCES 22
2.1.2.1 Key data from primary sources 23
2.1.2.2 Insights from primary experts 23
2.1.2.3 Breakdown of primary interviews 24
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE (SUPPLY & DEMAND SIDE) AND DESIGNATION 24
2.2 MARKET SIZE ESTIMATION 25
FIGURE 5 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 25
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 26
FIGURE 7 DEMAND-SIDE APPROACH 28
2.3 DATA TRIANGULATION 29
FIGURE 8 DATA TRIANGULATION METHODOLOGY 29
2.4 MARKET RANKING ANALYSIS 30
2.5 ASSUMPTIONS FOR THE STUDY 30
2.6 LIMITATIONS 31
2.6.1 METHODOLOGY-RELATED LIMITATIONS 31
2.6.2 SCOPE-RELATED LIMITATIONS 31
2.7 RISK ASSESSMENT 31
TABLE 2 RISK ASSESSMENT: US HEALTHCARE ENVIRONMENTAL SERVICES MARKET 31
 
3 EXECUTIVE SUMMARY 32
FIGURE 9 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 32
FIGURE 10 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET,
BY FACILITY TYPE, 2021 VS. 2026 (USD MILLION) 33
4 PREMIUM INSIGHTS 34
4.1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET OVERVIEW 34
FIGURE 11 STRINGENT REGULATORY GUIDELINES ON INFECTION CONTROL & PREVENTION METHODS IS A KEY FACTOR DRIVING THE MARKET GROWTH 34
4.2 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE AND FACILITY TYPE 35
FIGURE 12 JANITORIAL/CORE-CLEANING SERVICES ACCOUNTED FOR THE LARGEST SHARE OF THE US HEALTHCARE ENVIRONMENTAL SERVICES
MARKET IN 2020 35
4.3 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE (2021–2026) 36
FIGURE 13 ACUTE CARE FACILITIES TO DOMINATE THE US HEALTHCARE ENVIRONMENTAL SERVICES MARKET DURING THE FORECAST PERIOD 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
TABLE 3 MARKET DYNAMICS: HEALTHCARE ENVIRONMENTAL SERVICES MARKET 37
5.2.1 MARKET DRIVERS 38
5.2.1.1 Increasing prevalence of Hospital-acquired infections (HAIs) 38
5.2.1.2 Rising number of hospital admissions and surgeries 39
TABLE 4 US: PERCENTAGE INCREASE IN THE NUMBER OF SURGERIES PERFORMED 39
FIGURE 14 TOTAL ADMISSIONS IN ALL US HOSPITALS 40
FIGURE 15 TOTAL NUMBER OF HOSPITALS IN THE US 40
5.2.1.3 Shortage of in-house expertise and the rising need to reduce healthcare costs 41
5.2.1.4 Increasing outsourcing of cleaning services 41
5.2.2 MARKET RESTRAINTS 41
5.2.2.1 Healthcare facilities with an in-house EVS department 41
5.2.3 MARKET OPPORTUNITIES 42
5.2.3.1 Sustained acquisitions among strategic & financial buyers 42
TABLE 5 COMPANY ACQUISITIONS 42
5.2.4 MARKET CHALLENGES 42
5.2.4.1 Noncompliance with cleaning standards by EVS providers 42
5.3 INDUSTRY TRENDS 43
5.3.1 EMERGENCE OF NEW SURFACE DISINFECTANTS &
GREEN CLEANING PRODUCTS 43
5.3.2 DISINFECTION ROBOTS 44
5.3.3 MONITORING TOOLS FOR CLEANING QUALITY ASSESSMENT 44
5.4 TECHNOLOGY ANALYSIS 45
TABLE 6 TECHNOLOGY INNOVATION IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 45
5.5 PATENT ANALYSIS 45
5.5.1 PATENT PUBLICATION TRENDS FOR HEALTHCARE ENVIRONMENTAL SERVICES 46
FIGURE 16 PATENT PUBLICATION TRENDS (JANUARY 2011–DECEMBER 2021) 46
5.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS 47
FIGURE 17 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 47
FIGURE 18 TOP APPLICANT COUNTRIES/REGIONS FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 48
TABLE 7 LIST OF PATENTS/PATENT APPLICATIONS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET, 2020–2021 48
5.6 IMPACT OF COVID-19 ON THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 50
6 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE 51
6.1 INTRODUCTION 52
TABLE 8 US: HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 52
6.2 JANITORIAL SERVICES/CORE-CLEANING SERVICES 52
6.2.1 MANDATORY REGULAR CLEANING AND DISINFECTION OF HEALTHCARE FACILITIES TO DRIVE THE MARKET GROWTH 52
6.3 INFECTION PREVENTION & CONTROL SERVICES 53
TABLE 9 US: INFECTION PREVENTION & CONTROL SERVICE MARKET, BY TYPE,
2019–2026 (USD MILLION) 53
6.3.1 SPECIALIZED CLEANING SERVICES 53
6.3.1.1 Rising adoption of specialized services to reduce HAIs to drive the market growth 53
6.3.2 INFECTION PREVENTION & CONTROL CONSULTATION SERVICES 53
6.3.2.1 The provision of customized environmental services specific
to a healthcare facility ensures market demand 53
6.4 ENHANCED CLEANING TECHNOLOGY 54
6.4.1 RISING DEMAND FOR ADVANCED CLEANING SOLUTIONS TO DRIVE THE SEGMENT GROWTH 54
TABLE 10 EXAMPLES OF COMPANIES PROVIDING TECHNOLOGY & INNOVATION IN HEALTHCARE EVS 54
6.5 FRONT-OF-HOUSE CLEANING AND BRAND EXPERIENCE 56
6.5.1 RISING AWARENESS TOWARDS A CLEAN AND SAFE ENVIRONMENT DURING PANDEMICS TO SUSTAIN THE MARKET GROWTH 56
6.6 OTHER SERVICES 56
 
7 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE 57
7.1 INTRODUCTION 58
FIGURE 19 STATES WITH THE HIGHEST NUMBER OF COVID-19 ADMISSIONS
(FEBRUARY 2022) 58
TABLE 11 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE, 2019–2026 (USD MILLION) 59
7.2 ACUTE-CARE FACILITIES 59
TABLE 12 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR ACUTE-CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 59
7.2.1 ACUTE HOSPITALS 60
7.2.1.1 Increasing hospital admissions due to COVID-19 and the rising prevalence of HAIs propel the market growth 60
FIGURE 20 NUMBER OF HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS
IN THE US (2020) 60
FIGURE 21 HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS IN THE US (2020) 61
FIGURE 22 HAIS REPORTED BY CRITICAL ACCESS HOSPITALS (CAHS) IN THE US (2018) 61
7.2.2 MILITARY TREATMENT FACILITY 61
7.2.2.1 The increasing number of military ambulatory health services & funding to drive the market growth 61
FIGURE 23 MILITARY HEALTH SYSTEMS FACILITIES IN THE US (2021) 62
7.2.3 CHILDREN’S HOSPITALS 62
7.2.3.1 Rising cases of COVID-19 and infection-related mortality rates among children drive the market growth 62
7.2.4 AMBULATORY SURGERY CENTERS (ASCS) 63
7.2.4.1 ASCs save time and reduce the risk of HAIS; key factor driving the market growth 63
FIGURE 24 US SURGERY CASES BY SETTING: ASC VS. HOPD (2005-2020) 64
7.2.5 ACADEMIC MEDICAL CENTERS (AMCS) 64
7.2.5.1 Healthcare capacity expansion during COVID-19 drives the adoption of healthcare environmental services in AMCs 64
7.3 POST-ACUTE CARE FACILITIES 64
TABLE 13 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR POST-ACUTE CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 65
7.3.1 LONG-TERM ACUTE HOSPITALS (LTACH) 65
7.3.1.1 Increasing risk of infection due to prolonged hospital stays to drive the market growth 65
7.3.2 SKILLED NURSING FACILITIES (SNF) 66
7.3.2.1 Increasing admissions of elderly people in skilled nursing facilities to drive the market growth 66
7.3.3 OTHER POST-ACUTE CARE FACILITIES 66
7.4 NON-ACUTE CARE FACILITIES 67
TABLE 14 US: ENVIRONMENTAL SERVICES MARKET FOR NON-ACUTE CARE SETTINGS, BY TYPE, 2019–2026 (USD MILLION) 67
7.4.1 PHYSICIAN’S OFFICES AND CLINICS 67
7.4.1.1 High patient traffic leads to continuous cleaning & maintenance to drive the market growth 67
7.4.2 OTHER NON-ACUTE CARE FACILITIES 68
FIGURE 25 DISTRIBUTION OF INDUSTRY MEDICAL AND HEALTH R&D INVESTMENTS,
BY SEGMENT (2020) 68
8 COMPETITIVE LANDSCAPE 70
8.1 OVERVIEW 70
8.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 70
8.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 71
8.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 72
8.4 MARKET RANKING ANALYSIS 73
FIGURE 27 US HEALTHCARE ENVIRONMENTAL SERVICE MARKET RANKING,
BY KEY PLAYER, 2020 73
8.5 COMPETITIVE BENCHMARKING 75
TABLE 15 FOOTPRINT OF COMPANIES IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 75
TABLE 16 SERVICE FOOTPRINT OF COMPANIES 76
TABLE 17 END-USER FOOTPRINT OF COMPANIES 77
8.6 COMPETITIVE LEADERSHIP MAPPING 77
8.6.1 STARS 78
8.6.2 EMERGING LEADERS 78
8.6.3 PERVASIVE PLAYERS 78
8.6.4 PARTICIPANTS 78
FIGURE 28 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET:
COMPETITIVE LEADERSHIP MAPPING (2021) 79
8.7 COMPETITIVE SCENARIO 80
8.7.1 SERVICE APPROVALS/ENHANCEMENTS 80
8.7.2 DEALS 81
TABLE 19 DEALS, 2018–2022 81
8.7.3 OTHER DEVELOPMENTS 82
9 COMPANY PROFILES 83
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
9.1 SODEXO GLOBAL 83
TABLE 21 SODEXO GLOBAL: BUSINESS OVERVIEW 83
FIGURE 29 SODEXO GLOBAL: COMPANY SNAPSHOT (2021) 84
9.2 COMPASS GROUP (CROTHALL HEALTHCARE (US)) 87
TABLE 22 COMPASS GROUP: BUSINESS OVERVIEW 87
FIGURE 30 COMPASS GROUP: COMPANY SNAPSHOT (2021) 88
 
9.3 ARAMARK CORPORATION 90
TABLE 23 ARAMARK CORPORATION: BUSINESS OVERVIEW 90
FIGURE 31 ARAMARK CORPORATION: COMPANY SNAPSHOT (2021) 91
9.4 HOSPITAL HOUSEKEEPING SYSTEMS (HHS) (US) 94
TABLE 24 HOSPITAL HOUSEKEEPING SYSTEMS (HHS): BUSINESS OVERVIEW 94
9.5 HEALTHCARE SERVICES GROUP, INC. 97
TABLE 25 HEALTHCARE SERVICES GROUP, INC.: BUSINESS OVERVIEW 97
FIGURE 32 HEALTHCARE SERVICES GROUP: COMPANY SNAPSHOT (2020) 98
9.6 ABM INDUSTRIES INCORPORATED 100
TABLE 26 ABM INDUSTRIES INCORPORATED: BUSINESS OVERVIEW 100
FIGURE 33 ABM INDUSTRIES INCORPORATED: COMPANY SNAPSHOT (2020) 101
9.7 OCTOCLEAN 103
TABLE 27 OCTOCLEAN: BUSINESS OVERVIEW 103
9.8 SERVICEMASTER CLEAN (SERVICEMASTER TBS) 105
TABLE 28 SERVICEMASTER CLEAN.: BUSINESS OVERVIEW 105
9.9 CORVUS JANITORIAL SYSTEMS 107
TABLE 29 CORVUS JANITORIAL SYSTEMS: BUSINESS OVERVIEW 107
9.10 BRAVO! BUILDING SERVICES 109
TABLE 30 BRAVO! BUILDING SERVICES: BUSINESS OVERVIEW 109
9.11 POWERLINK ENVIRONMENTAL SERVICES, LLC 111
TABLE 31 POWERLINK ENVIRONMENTAL SERVICES, LLC: BUSINESS OVERVIEW 111
9.12 JANI-KING INTERNATIONAL, INC. 112
TABLE 32 JANI- KING INTERNATIONAL, INC: BUSINESS OVERVIEW 112
9.13 AVI FOOD SYSTEMS(US) 114
TABLE 33 AVI FOOD SYTEMS, INC.: BUSINESS OVERVIEW 114
9.14 SERVICON 115
TABLE 34 SERVICON: BUSINESS OVERVIEW 115
9.15 XANITOS, INC. 117
TABLE 35 XANITOS, INC.: BUSINESS OVERVIEW 117
9.16 STATHAKIS 119
TABLE 36 STATHAKIS: BUSINESS OVERVIEW 119
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
10 APPENDIX 120
10.1 INSIGHTS FROM INDUSTRY EXPERTS 120
10.2 DISCUSSION GUIDE 121
10.3 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 124
10.4 AVAILABLE CUSTOMIZATIONS 126
10.5 RELATED REPORTS 126
10.6 AUTHOR DETAILS 127